snowhmr schreef op 15 maart 2021 09:49:
Feb 24 (Reuters) - Novacyt Sa :
SAYS IS CONTINUING TO BUILD ON ITS STRATEGY FOR DELIVERING A SUSTAINABLE, LONG-TERM DIAGNOSTICS BUSINESS.
SAYS INTENDS TO PRESENT THESE PLANS DURING Q2 2021.
ANNOUNCES AN EXPANSION OF SNPSIG(®) PORTFOLIO TO DETECT NEW SARS-COV-2 VARIANTS OF CONCERN, INCLUDING A SPECIFIC VARIANT PREVALENT IN US
FLAGS LAUNCH OF CE MARK COVID-HT DIRECT, A NEXT GENERATION DIRECT-TO-PCR SARS-COV-2 TEST FOR HIGH-THROUGHPUT LABORATORIES
DEVELOPMENT OF COVID-19 ANTIBODY LATERAL FLOW TESTDEVELOPMENT OF LOOP-MEDIATED ISOTHERMAL AMPLIFICATION COVID-19 TEST
DEVELOPMENT OF AN INNOVATIVE ASSAY PANEL FOR DETECTION OF ASPERGILLUS, A RESPIRATORY FUNGAL INFECTION ASSOCIATED WITH CO-INFECTION RISK IN PATIENTS WITH COVID-19
SAYS QUEEN MARY UNIVERSITY OF LONDON HAS SUCCESSFULLY COMPLETED CLINICAL TRIAL OF RAPID TESTING IN CARE HOMES USING COMPANY'S RAPID PCR SYSTEM
SAYS VARIANT DIAGNOSTIC SURVEILLANCE STUDY HAS INITIATED IN UK, UNITED STATES, AND LATIN AMERICA
EXPECTS TO LAUNCH ITS COVID LATERAL FLOW TEST IN Q2 2021Further company coverage:
Volgens dit bericht hebben ze beide in ontwikkeling.